Max Robotics — Global Service Robot Directory + US Certification

About

Sarah Lidagoster is a urologic oncologist whose research focuses on optimizing surgical outcomes and precision prognostics for bladder cancer patients. Her work centers on two critical frontiers: the safety of novel immunotherapy-based neoadjuvant regimens prior to radical cystectomy, and the use of circulating tumor DNA (ctDNA) to refine risk stratification. In her most-cited study (2025, 4 citations), she conducted a bi-center analysis demonstrating that patients receiving immunotherapy-based neoadjuvant treatment before robot-assisted radical cystectomy (RARC) do not experience elevated 30- or 90-day postoperative complication rates—a key finding that supports the integration of these emerging therapies into standard care. Her 2024 study (1 citation) explores the prognostic value of ctDNA in patients with positive lymph node disease after RARC, offering a contemporary, molecularly-informed approach to identifying those at highest risk for recurrence. By bridging the gap between cutting-edge systemic therapy and surgical safety, Lidagoster is helping to shape a more personalized, evidence-based framework for managing aggressive bladder cancer. Her work is particularly valuable for clinicians and researchers seeking to balance oncologic efficacy with perioperative risk in the era of immunotherapy.